Galina Baranova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Galina Baranova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Svitlana Zahorodnia
Department of Virus Reproduction, D.K. Zabolotny Institute of Microbiology and Virology of the NASU, Kyiv 03143, Ukraine
6 shared publications - Anna Golovan
D.K. Zabolotny Institute of microbiology and virology NAS of Ukraine, Kyiv, Ukraine
4 shared publications - Krystyna Naumenko
D.K. Zabolotny Institute of microbiology and virology NAS of Ukraine, Kyiv, Ukraine
4 shared publications - Anna Golovan
D.K. Zabolotny Institute of microbiology and virology NAS of Ukraine, Kyiv, Ukraine
2 shared publications - Yuriy G. Shermolovich
Institute of Organic Chemistry NAS of Ukraine, Murmanska Str. 5, 02660 Kyiv, Ukraine
2 shared publications - Ganna Gudz
Institute of Organic Chemistry, National Academy of Sciences of Ukraine, 5, Murmanska str., 02660 Kyiv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 31 October 2018
- Published by MDPI AG
Antiviral effect of derivatives of triazoles on EBV-associated lymphoblastoid cells
Epstein–Barr virus (EBV) causes lymphocyte-proliferative diseases, such as Burkitt’s lymphoma, Hodgkin’s lymphoma, other B and T cell lymphomas. Recently the connection between EBV and autoimmunity diseases has been demonstrated. In recent years, several studies have explored the concept that the compounds that have anti-herpetic activity might be able to influence the cell cycle of infected cells, by eliminating them from the body. However, cell cycle regulation during EBV-infection and the effect of anti-EBV drugs have received only limited attention. The aim of our work was to study derivatives of triazole (G14, G20, G22, and G24) as potential antiherpetic agent and their effect on the cell cycle of lymphoblastoid cell lines B95-8. According to PCR, anti-EBV activity was observed only for compounds G14 and G22, EC50 values were 27 and 100µg/ml. The В95-8 cells treated with all studied compounds were analyzed with the help of flow cytometry (cells were stained with propidium iodide). It was observed an induction of apoptosis in the presence of G22 at 700µg/ml; the proportion of apoptotic cells reached almost 40%. Other compounds G14 and G24 led to the switch of cells from the Sub G0 phase of the cell cycle to the G1 phase and subsequent activation of the S-phase. These compounds may play an important role as potential inducers of EBV lytic infection; with the addition of antiherpesvirus drugs, they could be therapeutically beneficial for EBV-associated tumors.
- 31 October 2018
- Published by MDPI AG
Open AccessAntiviral effect of derivatives of triazoles on EBV-associated lymphoblastoid cells
Epstein–Barr virus (EBV) causes lymphocyte-proliferative diseases, such as Burkitt’s lymphoma, Hodgkin’s lymphoma, other B and T cell lymphomas. Recently the connection between EBV and autoimmunity diseases has been demonstrated. In recent years, several studies have explored the concept that the compounds that have anti-herpetic activity might be able to influence the cell cycle of infected cells, by eliminating them from the body. However, cell cycle regulation during EBV-infection and the effect of anti-EBV drugs have received only limited attention. The aim of our work was to study derivatives of triazole (G14, G20, G22, and G24) as potential antiherpetic agent and their effect on the cell cycle of lymphoblastoid cell lines B95-8. According to PCR, anti-EBV activity was observed only for compounds G14 and G22, EC50 values were 27 and 100µg/ml. The В95-8 cells treated with all studied compounds were analyzed with the help of flow cytometry (cells were stained with propidium iodide). It was observed an induction of apoptosis in the presence of G22 at 700µg/ml; the proportion of apoptotic cells reached almost 40%. Other compounds G14 and G24 led to the switch of cells from the Sub G0 phase of the cell cycle to the G1 phase and subsequent activation of the S-phase. These compounds may play an important role as potential inducers of EBV lytic infection; with the addition of antiherpesvirus drugs, they could be therapeutically beneficial for EBV-associated tumors.
- Open Access
- 1 November 2017
- Published by MDPI AG
Antiviral Activity of Extracts from Wild Grasses against Epstein-Barr Virus and Induction of Apoptosis in EBV-positive Lymphoblastoid Cells
Epstein-Barr virus (EBV) belongs to the human herpes virus family that infects more than 90% of the population. EBV is associated with a number of lymphoproliferative and autoimmune diseases. Use of the drugs, which would not only inhibit the reproduction of the virus, but also would stimulate the elimination of tumor cells, is important for the treatment of virus-associated tumors. In the current research the antiviral effects of the herbal extracts Proteflazid and Neoflazid were studied on the models of latent, acute and chronic EBV infections in Raji and B95-8 lymphoblastoid cells. Neoflazid was more toxic towards Raji cells than Proteflazid: the CC50 indices were 8 µg/ml and 36 µg/ml respectively. Toxicities of these compounds in B95-8 cells were almost the same and their CC50 indices were close to 25 µg/ml. Both drugs showed high antiviral activity against EBV lytic infection in Raji cells and EC50 was 0.02 and 0.083 µg/ml for Proteflazid and Neoflazid, respectively, and selectivity indinces were 1800 and 96. They were less effective in B95-8 cells and even at a concentration of 10 µg/ml these compounds inhibited virus replication by only 10-19%. We checked the ability of Proteflazid to induce apoptosis and found that the drug stimulated the apoptotic cell death in latent and lytic EBV infections at cytotoxic concentrations (30 µg/ml). The non-toxic concentration (5 µg/ml) induced apoptosis more actively (by 10%) during EBV lytic infection in cells B95-8 than in the case of latent infection in Raji cells.
- 1 November 2017
- Published by MDPI AG
Open AccessAntiviral Activity of Extracts from Wild Grasses against Epstein-Barr Virus and Induction of Apoptosis in EBV-positive Lymphoblastoid Cells
Epstein-Barr virus (EBV) belongs to the human herpes virus family that infects more than 90% of the population. EBV is associated with a number of lymphoproliferative and autoimmune diseases. Use of the drugs, which would not only inhibit the reproduction of the virus, but also would stimulate the elimination of tumor cells, is important for the treatment of virus-associated tumors. In the current research the antiviral effects of the herbal extracts Proteflazid and Neoflazid were studied on the models of latent, acute and chronic EBV infections in Raji and B95-8 lymphoblastoid cells. Neoflazid was more toxic towards Raji cells than Proteflazid: the CC50 indices were 8 µg/ml and 36 µg/ml respectively. Toxicities of these compounds in B95-8 cells were almost the same and their CC50 indices were close to 25 µg/ml. Both drugs showed high antiviral activity against EBV lytic infection in Raji cells and EC50 was 0.02 and 0.083 µg/ml for Proteflazid and Neoflazid, respectively, and selectivity indinces were 1800 and 96. They were less effective in B95-8 cells and even at a concentration of 10 µg/ml these compounds inhibited virus replication by only 10-19%. We checked the ability of Proteflazid to induce apoptosis and found that the drug stimulated the apoptotic cell death in latent and lytic EBV infections at cytotoxic concentrations (30 µg/ml). The non-toxic concentration (5 µg/ml) induced apoptosis more actively (by 10%) during EBV lytic infection in cells B95-8 than in the case of latent infection in Raji cells.
- Open Access
- 17 November 2016
- Published by MDPI AG in Proceedings
- Vol. 1 (2) , 34
Application of SPR Analysis for Detection of Specific Antibodies in Human Blood Serum
SPR technique possesses rich potential possibilities for investigation of different aspects of virus-specific agent interaction and modification of structure of viruses, induced by external factors. Аccording to World Health Organization, viruses of Herpesviridae family infect 90% of the Earth’s population. Herpetic infection is urgent for several spheres of medicine: infectology, infectious neurology, transplanthology, haemotology. It is perspective today using of biosensor technologies for developing of diagnostic systems. The aim of this work is develop and characteristics of biosensor chips for detection specific antibodies to herpes simplex virus and Epstein-Barr virus in patients’ blood sera. The study was performed using the device “Plasmon-6”, which is a computer-controlled optoelectronic spectrometer, which uses the SPR phenomenon in the optical configuration Kretschmann. It is developed at the Institute of Semiconductor Physics NAS of Ukraine. The advantage of this device is a compact design; full record of kinetic dependence; the minimum of one measurement: 0.2 s (mode slope); measurement in the gas or liquid; additional analog channel. We used additional channel as a control one. This allowed neutralize influences of environmental (temperature, humidity and another) at its operation. As antigens used purified proteins of viruses derived from cell cultures. The selection of sera was carried out using test kits “HSV-1 IgG ELISA” and «EBV VCA IgG ELISA» (GenWay, San Diego, CA, USA). Immobilization of viral proteins on sensor surface was performed using 0.2% solution of Dextran 17 000 (Sigma, St Louis, MO, USA). It was found direct dependence between amount of immobilized antigen and SPR response. The immobilization 8 × 10−5 mg/mm2 of viral proteins on the surface of the chip was optimal for detection of antibodies. About 200 samples positive and negative blood sera of patients were tested who were previously tested by ELISA and created combined pools with varying degrees load of antibodies to studied virus. The limits of positive and negative response for SPR analysis was determined by using panel of negative blood sera of donors. SPR data were agreed with ELISA results in 84% of samples. The reproducibility of results varied between 85% and 95%. Thus, in this study biosensor chip for detection of specific antibodies to HSV-1 and EBV was successfully developed for express diagnostic of these pathogens.
- 17 November 2016
- Published by MDPI AG in Proceedings
- Vol. 1 (2) , 34
Open AccessApplication of SPR Analysis for Detection of Specific Antibodies in Human Blood Serum
SPR technique possesses rich potential possibilities for investigation of different aspects of virus-specific agent interaction and modification of structure of viruses, induced by external factors. Аccording to World Health Organization, viruses of Herpesviridae family infect 90% of the Earth’s population. Herpetic infection is urgent for several spheres of medicine: infectology, infectious neurology, transplanthology, haemotology. It is perspective today using of biosensor technologies for developing of diagnostic systems. The aim of this work is develop and characteristics of biosensor chips for detection specific antibodies to herpes simplex virus and Epstein-Barr virus in patients’ blood sera. The study was performed using the device “Plasmon-6”, which is a computer-controlled optoelectronic spectrometer, which uses the SPR phenomenon in the optical configuration Kretschmann. It is developed at the Institute of Semiconductor Physics NAS of Ukraine. The advantage of this device is a compact design; full record of kinetic dependence; the minimum of one measurement: 0.2 s (mode slope); measurement in the gas or liquid; additional analog channel. We used additional channel as a control one. This allowed neutralize influences of environmental (temperature, humidity and another) at its operation. As antigens used purified proteins of viruses derived from cell cultures. The selection of sera was carried out using test kits “HSV-1 IgG ELISA” and «EBV VCA IgG ELISA» (GenWay, San Diego, CA, USA). Immobilization of viral proteins on sensor surface was performed using 0.2% solution of Dextran 17 000 (Sigma, St Louis, MO, USA). It was found direct dependence between amount of immobilized antigen and SPR response. The immobilization 8 × 10−5 mg/mm2 of viral proteins on the surface of the chip was optimal for detection of antibodies. About 200 samples positive and negative blood sera of patients were tested who were previously tested by ELISA and created combined pools with varying degrees load of antibodies to studied virus. The limits of positive and negative response for SPR analysis was determined by using panel of negative blood sera of donors. SPR data were agreed with ELISA results in 84% of samples. The reproducibility of results varied between 85% and 95%. Thus, in this study biosensor chip for detection of specific antibodies to HSV-1 and EBV was successfully developed for express diagnostic of these pathogens.
- Open Access
- 1 November 2016
- Published by MDPI AG
Antiviral and Apoptosis Modulating Potential of Fluorinated Compounds
In our laboratory, we focus on the design, synthesis, and evaluation of fluorinated compounds that could be used in the tretament of diseases caused by the Epstein-Barr virus (EBV) and virus vesicular stomatitis (VVS). EBV is a DNA-containing virus. It is characterized by an acute form of infection as well as a latent form, which may lead to cell transformation and to cancer (lymphoma, carcinoma). VVS is a RNA-containing virus. For this purpose, in a first step, we used the PASS software by which we could identify potential antiviral candidates among which a fluorinated derivative of uracil (G27), a trifluoromethyl-substituted derivative of a thiosugar (SBIO6), a bisphosphonic acid (10s19) and several derivatives of alanin and glucose (10s20 - 10s28). Our in vitro studies revealed an antiviral activity for a few compounds. Three compounds appeared to be effective against EBV: G27 (EC50 = 100 µg/ml), 10s20 (EC50 = µg/ml), and 10s25 (EC50 50 = 19 µg/ml) and for compound 10s24 (EC50 = 29 µg/ml). It was established that the index of selectivity for these compounds ranged from 10 to 100. As Epstein-Barr virus (EBV) is the cause of several lymphoproliferative diseases, we studied the potency of G27 and SBIO6 compounds to make an apoptosis induction. Apoptotic cells were detected using a flow cytometry. Addition of G27 led to the observation of two peaks in the histogram, what may indicate a break of the cell cycle by this compound. It was also established that by addition of SBIO6 the percentage of apoptotic cells was significantly increased when compared to the control and reached 70 - 90 percent.
- 1 November 2016
- Published by MDPI AG
Open AccessAntiviral and Apoptosis Modulating Potential of Fluorinated Compounds
In our laboratory, we focus on the design, synthesis, and evaluation of fluorinated compounds that could be used in the tretament of diseases caused by the Epstein-Barr virus (EBV) and virus vesicular stomatitis (VVS). EBV is a DNA-containing virus. It is characterized by an acute form of infection as well as a latent form, which may lead to cell transformation and to cancer (lymphoma, carcinoma). VVS is a RNA-containing virus. For this purpose, in a first step, we used the PASS software by which we could identify potential antiviral candidates among which a fluorinated derivative of uracil (G27), a trifluoromethyl-substituted derivative of a thiosugar (SBIO6), a bisphosphonic acid (10s19) and several derivatives of alanin and glucose (10s20 - 10s28). Our in vitro studies revealed an antiviral activity for a few compounds. Three compounds appeared to be effective against EBV: G27 (EC50 = 100 µg/ml), 10s20 (EC50 = µg/ml), and 10s25 (EC50 50 = 19 µg/ml) and for compound 10s24 (EC50 = 29 µg/ml). It was established that the index of selectivity for these compounds ranged from 10 to 100. As Epstein-Barr virus (EBV) is the cause of several lymphoproliferative diseases, we studied the potency of G27 and SBIO6 compounds to make an apoptosis induction. Apoptotic cells were detected using a flow cytometry. Addition of G27 led to the observation of two peaks in the histogram, what may indicate a break of the cell cycle by this compound. It was also established that by addition of SBIO6 the percentage of apoptotic cells was significantly increased when compared to the control and reached 70 - 90 percent.
- Open Access
- 1 November 2016
- Published by MDPI AG
Antiviral Activity of a Substance from Yeast RNA
Inhibition of virus-cell interactions, which are required for virus replication, constitutes an exciting area of research for the discovery of novel antiviral agents. RNA based drugs are in clinical use for treatment of infectious diseases as immunomodulators, anti-inflammatory and antiviral agents. Nuclex, a low molecular weight exogenous yeast RNA, consists of a pure, homogeneous 25-membered oligonucleotide. The preventive and therapeutic effects of Nuclex were demonstrated against pandemic strains of influenza virus, parainfluenza virus, Hepatitis C, Herpes simplex virus types 1 and 2, cytomegalovirus, and HIV on experimental models in vitro and in vivo. The mechanism of the antiviral action of the drug relies on its ability to change conformations of cell regulatory proteins and viral coat proteins. An antiviral effect of Nuclex against Epstein-Barr virus (EBV) etiological agent of infectious mononucleosis associated with a number of lymphoproliferative and autoimmune diseases was studied in this work. The study was performed with EBV-positive human B-cells (Raji) – latently infected with EBV, and EBV-producing tamarin (Saguinus oedipus) B-cell line (B95-8). The drug c ytotoxicity was assessed by MTT-method. As a result of investigations it was found that the drug has low toxicity relative to both lymphoblastoid cell cultures. The i nhibitory concentrations suppressing 10% of cell viability (IC10) were 2000 µg/ml and IC50s (50% inhibited cell viability) were 5000 µg/ml for both cell lines. An antiviral activity of Nuclex was measured by PCR in EBV infected cells Raji, as a model of acute infection and in non-induced B95-8 cells as a model of chronic EBV infection after 48 hours incubation. The drug effectively inhibited viral replication in the studied concentration range from 10 to 500 µg/ml in EBV-infected Raji cells and B95-8 cells. Effective concentration of Nuclex that inhibited 90% level of the viral DNA accumulation (EC90) was 50 µg/ml for in both cell lines. A virucidal activity of the drug was investigated considering the ability of Nuclex to influence the conformation of the viral surface proteins. The levels of inhibition of the EBV DNA accumulation were 30% after incubation of the drug at the concentration 100 µg/ml with the EBV for the 30 and 60 min exposures and the subsequent infection of Raji cells incubated for 48 hours, while 50% inhibition of viral DNA accumulation was observed at the drug concentration 200 µg/ml under 30 min exposure and 30% at 60 min exposure. Thus Nuclex showed a strong antiviral effect against EBV. Considering an antiviral activity of the drug (EC90) at 50 µg/ml, and a virucidal action EC50 at 200 µg/ml, determination of its mechanism of action, which could be related to siRNA properties, will constitute the next stage of our research.
- 1 November 2016
- Published by MDPI AG
Open AccessAntiviral Activity of a Substance from Yeast RNA
Inhibition of virus-cell interactions, which are required for virus replication, constitutes an exciting area of research for the discovery of novel antiviral agents. RNA based drugs are in clinical use for treatment of infectious diseases as immunomodulators, anti-inflammatory and antiviral agents. Nuclex, a low molecular weight exogenous yeast RNA, consists of a pure, homogeneous 25-membered oligonucleotide. The preventive and therapeutic effects of Nuclex were demonstrated against pandemic strains of influenza virus, parainfluenza virus, Hepatitis C, Herpes simplex virus types 1 and 2, cytomegalovirus, and HIV on experimental models in vitro and in vivo. The mechanism of the antiviral action of the drug relies on its ability to change conformations of cell regulatory proteins and viral coat proteins. An antiviral effect of Nuclex against Epstein-Barr virus (EBV) etiological agent of infectious mononucleosis associated with a number of lymphoproliferative and autoimmune diseases was studied in this work. The study was performed with EBV-positive human B-cells (Raji) – latently infected with EBV, and EBV-producing tamarin (Saguinus oedipus) B-cell line (B95-8). The drug c ytotoxicity was assessed by MTT-method. As a result of investigations it was found that the drug has low toxicity relative to both lymphoblastoid cell cultures. The i nhibitory concentrations suppressing 10% of cell viability (IC10) were 2000 µg/ml and IC50s (50% inhibited cell viability) were 5000 µg/ml for both cell lines. An antiviral activity of Nuclex was measured by PCR in EBV infected cells Raji, as a model of acute infection and in non-induced B95-8 cells as a model of chronic EBV infection after 48 hours incubation. The drug effectively inhibited viral replication in the studied concentration range from 10 to 500 µg/ml in EBV-infected Raji cells and B95-8 cells. Effective concentration of Nuclex that inhibited 90% level of the viral DNA accumulation (EC90) was 50 µg/ml for in both cell lines. A virucidal activity of the drug was investigated considering the ability of Nuclex to influence the conformation of the viral surface proteins. The levels of inhibition of the EBV DNA accumulation were 30% after incubation of the drug at the concentration 100 µg/ml with the EBV for the 30 and 60 min exposures and the subsequent infection of Raji cells incubated for 48 hours, while 50% inhibition of viral DNA accumulation was observed at the drug concentration 200 µg/ml under 30 min exposure and 30% at 60 min exposure. Thus Nuclex showed a strong antiviral effect against EBV. Considering an antiviral activity of the drug (EC90) at 50 µg/ml, and a virucidal action EC50 at 200 µg/ml, determination of its mechanism of action, which could be related to siRNA properties, will constitute the next stage of our research.
- Open Access
- 2 November 2015
- Published by MDPI AG
Study of the antiviral activity of the nucleoside analogue 2-(beta-D-ribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one against Epstein-Barr virus
Study of the antiviral action of the abnormal nucleoside analogue 2-(beta-D-ribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one was performed with Epstein-Barr virus (EBV) positive human B-cells (Raji) superinfected by EBV, as an acute infection model, and EBV-producing tamarin (Saguinus oedipus) B-cell line (B95-8), as a chronic infection model. The antiviral activity of the compound was determined by RT-PCR. It was shown that the IC50 values (concentration of compound that inhibits the accumulation of the viral genome at 50 %) for 2-(beta-D-ribofuranosyl-5-amino-1,2,4-triazine-3(2H)-one were 0.5 ug/ml for the acute infection of EBV infected Raji cells and 3.8 ug/ml for the model of chronic infection. The anti-EBV action of Ganciclovir (the official anti-herpetic drug) was studied for comparison. IC50 values for Ganciclovir were 1.0 ug/ml for the acute model and 6.2 ug/ml for the chronic model of EBV infections. Thus abnormal nucleoside 2-(beta-D-ribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one is a promising anti-EBV compound deserving further research.
- 2 November 2015
- Published by MDPI AG
Open AccessStudy of the antiviral activity of the nucleoside analogue 2-(beta-D-ribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one against Epstein-Barr virus
Study of the antiviral action of the abnormal nucleoside analogue 2-(beta-D-ribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one was performed with Epstein-Barr virus (EBV) positive human B-cells (Raji) superinfected by EBV, as an acute infection model, and EBV-producing tamarin (Saguinus oedipus) B-cell line (B95-8), as a chronic infection model. The antiviral activity of the compound was determined by RT-PCR. It was shown that the IC50 values (concentration of compound that inhibits the accumulation of the viral genome at 50 %) for 2-(beta-D-ribofuranosyl-5-amino-1,2,4-triazine-3(2H)-one were 0.5 ug/ml for the acute infection of EBV infected Raji cells and 3.8 ug/ml for the model of chronic infection. The anti-EBV action of Ganciclovir (the official anti-herpetic drug) was studied for comparison. IC50 values for Ganciclovir were 1.0 ug/ml for the acute model and 6.2 ug/ml for the chronic model of EBV infections. Thus abnormal nucleoside 2-(beta-D-ribofuranosyl)-5-amino-1,2,4-triazine-3(2H)-one is a promising anti-EBV compound deserving further research.